PROKIDNEY CORP. (PROK)
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Address
2000 FRONTIS PLAZA BLVD.
WINSTON-SALEM, NC 27103
Founded
2015
Number of Employees
163
Website
http://www.prokidney.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | $9,499 | - | $9,499 |
| Average Price | - | - | - | - | - | - | - | - | - | $1.31 | - | $1.31 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 7,256,367 | - | 7,256,367 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 52.8% | - | 52.8% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | - | 31.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | 21.5% | - | 21.5% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 85% | - | 72% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at PROK make a trade.
Creating a free account takes less than one minute